

## Special Issue

# Management of National and Regional Immunization Programmes: Current Challenges and Future Strategies

### Message from the Guest Editors

In these challenging times of rising infection and cancer rates, particularly in low- and middle-income countries, it is essential that countries learn from each other in order to improve future access to vaccines and vaccination coverage where there are concerns across all target groups. As a result reduce future morbidity and mortality, including mortality due to antimicrobial resistance from inappropriate prescribing of antimicrobials. We welcome original research papers and reviews on these key topics, with insights and suggested ways forward for immunization programmes to enhance public health, including those for COVID-19. Topics of interest include, but are not limited to, issues and challenges surrounding vaccines, including vaccine hesitancy and vaccine uptake, strategies to address misinformation and build vaccine confidence, and key economic considerations, including affordability. Waivers and reduced publication fees will be available on request for a limited number of papers that will enhance this Special Issue, especially those from low- and low-middle income countries.



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



[mdpi.com/si/133062](https://www.mdpi.com/si/133062)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
vaccines@mdpi.com

[mdpi.com/journal/  
vaccines](https://www.mdpi.com/journal/vaccines)

### Guest Editors

Prof. Dr. Johanna C Meyer  
Dr. Sylvia Opanga  
Prof. Dr. Brian Godman

### Deadline for manuscript submissions

closed (30 September 2023)





# Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](http://mdpi.com/journal/vaccines)

## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

